NCT04252612撤回早期 1 期
Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Participant Compliance
研究概览
简要总结
This study will treat resectable cutaneous squamous cell carcinoma patients with pramlintide for two weeks prior to surgical resection of their tumor. Pre-treatment and surgical resection specimens will then be analyzed for biological alterations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven cutaneous squamous cell carcinoma. Mixed histologies (basaloid, spindle, sarcomatoid, etc.) are allowed if the pathology review favors squamous cell carcinoma as the majority component. Cancers of unknown primary sites are allowed if the clinical history and the site are highly suggestive of a skin cancer primary
- •Tumor site must be amenable for surgical resection and accessible for pre-treatment biopsy
- •Tumor site must be measurable by caliper measurements or by Response Evaluation Criteria in Solid Tumors (RECIST)1.1 imaging - lesions must be ≥1 cm
- •Eastern Cooperative Oncology Group (ECOG) ≤2 and be medically able to undergo surgical resection
- •Laboratory Requirements: Hemoglobin ≥ 8 g/dl, Platelet count ≥ 50,000/dl, Serum Creatinine ≤ 1.5 mg/dL OR Glomular Filtration Rate (GFR) ≥ 40, Serum aspartate aminotransferase (AST) and alanine transaminase (ALT) < 2.5x ULN; Total Bilirubin < 1.5x ULN (for patients with documented history of Gilbert's syndrome, total bilirubin level should be < 3.0 X ULN)
- •Ability to understand and willingness to sign a written informed consent document
- •Patients with child bearing potential must be willing to use barrier protection to prevent pregnancy while on study therapy and up to 30 days after the last dose of pramlintide
- •Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- •Patients must be willing to comply with the protocol for the duration of the treatment including daily sub-cutaneous (SQ) injections, biopsies, scheduled visits and examinations, radiologic studies, and surgical resection
排除标准
- •Type I diabetes: Type II diabetics (DM2) on insulin are allowed, however, for those DM2 patients that are on short acting insulin, the insulin dose should be reduced 50% and need to have regular glucose monitoring (see section 6.2.1). Type II diabetics not on insulin will not be eligible.
- •Patients with known gastroparesis
- •Patients with known allergic reactions to pramlintide or its ingredients
- •Pregnant women and/or nursing patients will be excluded from this study because of unknown risks to fetus or nursing infants
- •Any serious or uncontrolled medical disorder that could interfere with the current study as deemed by the investigating physician
- •Participation in any other clinical study using an investigational agent within 21 days of starting treatment on this protocol
- •No prior chemotherapy, radiation, or other tumor directed therapy within 21 days prior of starting treatment on this protocol
研究组 & 干预措施
Cohort 1: Pramlintide 60 mcg twice daily
Experimental
Participants will self inject Pramlintide 60 mcg twice daily for two weeks prior to surgical resection of tumor.
干预措施: Pramlintide (Drug)
Cohort 2: Pramlintide 60 mcg three times daily
Experimental
Participants will self inject Parmlintide 60 mcg three times daily for two weeks prior to surgical resection of tumor.
干预措施: Pramlintide (Drug)
Cohort 3: Pramlintide 120 mcg three times daily
Experimental
Participants will self inject Parmlintide 120 mcg three times daily for two weeks prior to surgical resection of tumor.
干预措施: Pramlintide (Drug)
结局指标
主要结局
Participant Compliance
时间窗: at 14 days from on study date
Patients who complete at least 75% of the injections and have not missed 2 consecutive days of treatment will be considered compliant.
次要结局
- Number of Adverse Events(at 44 days from on study date)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingNCT02040298University of California, San Francisco50
尚未招募
2 期
A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal CancerAdvanced Esophageal CarcinomaNCT06745193Peking University63
已完成
2 期
RAD001 and Bicalutamide for Androgen Independent Prostate CancerProstate CancerNCT00630344Dana-Farber Cancer Institute36
已完成
2 期
The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and NeckSquamous Cell Carcinoma of the Head and NeckNCT03057613Case Comprehensive Cancer Center18
终止
2 期
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple MyelomaMultiple MyelomaNCT00843310NYU Langone Health8